Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Medtronic plc    MDT   IE00BTN1Y115

MEDTRONIC PLC

(MDT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medtronic : First Procedures Performed in Trial of Technology for Atrial Fibrillation

03/04/2021 | 09:42am EDT

By Michael Dabaie

Medtronic PLC said the first procedures were performed in the investigational device exemption pivotal trial of the PulseSelect Pulsed Field Ablation System.

PulseSelect uses pulsed electric fields to treat atrial fibrillation.

The first procedure in the PULSED AF pivotal trial was performed this week at Southcoast Health in Fall River, Mass., with the second procedure also at Southcoast Health. The PULSED AF Trial aims to establish the safety and efficacy of the PulseSelect System.

Atrial fibrillation is one of the most common and undertreated heart rhythm disorders, affecting more than 37 million people worldwide. The disease involves an irregular quivering or rapid heart rhythm in the upper chambers of the heart.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

03-04-21 0942ET

All news about MEDTRONIC PLC
04/15MEDTRONIC  : Atlantic Equities Starts Medtronic at Overweight With $153 Price Ta..
MT
04/14MEDTRONIC  : Launches Extended Insulin Delivery Infusion Set in European
MT
04/14MEDTRONIC  : Announces European Launch of World's First Infusion Set with Wear u..
AQ
04/14MEDTRONIC  : Canada Named Top 50 Great Places To Work™ and Best Workplaces..
AQ
04/13MEDTRONIC  : U.S. FDA Grants De Novo Clearance for First and Only Artificial Int..
AQ
04/13MEDTRONIC  : U.S. FDA Grants De Novo Clearance for First and Only Artificial Int..
AQ
04/12MEDTRONIC  : Receives FDA De Novo Clearance for GI Genius Intelligent Endoscopy ..
MT
04/12MEDTRONIC  : U.S. FDA Grants De Novo Clearance for First and Only Artificial Int..
PR
04/12Medtronic Gets FDA Clearance for Colonoscopy Tool
DJ
04/12COSMO PHARMACEUTICALS N  : Wins US FDA Nod For New Endoscopy System
MT
More news
Financials (USD)
Sales 2021 29 985 M - -
Net income 2021 3 721 M - -
Net Debt 2021 21 975 M - -
P/E ratio 2021 46,0x
Yield 2021 1,80%
Capitalization 170 B 170 B -
EV / Sales 2021 6,39x
EV / Sales 2022 5,81x
Nbr of Employees 104 950
Free-Float 99,8%
Chart MEDTRONIC PLC
Duration : Period :
Medtronic plc Technical Analysis Chart | MDT | IE00BTN1Y115 | MarketScreener
Technical analysis trends MEDTRONIC PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Average target price 132,77 $
Last Close Price 125,85 $
Spread / Highest target 19,2%
Spread / Average Target 5,50%
Spread / Lowest Target -8,62%
EPS Revisions
Managers and Directors
NameTitle
Geoffrey Straub Martha Chairman & Chief Executive Officer
Karen L. Parkhill Chief Financial Officer & Executive Vice President
Richard E. Kuntz Senior VP, Chief Scientific & Clinical Officer
Mark Ploof Senior VP-Global Operations & Business Services
Richard H. Anderson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC5.77%169 655
ABBOTT LABORATORIES10.97%215 241
BECTON, DICKINSON AND COMPANY3.05%72 588
ALIGN TECHNOLOGY, INC.13.45%47 080
HOYA CORPORATION-4.87%46 185
BAXTER INTERNATIONAL INC.6.93%42 809